<DOC>
	<DOC>NCT01217892</DOC>
	<brief_summary>This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so, how it compares to treatment with metformin alone.</brief_summary>
	<brief_title>Evaluation of Dapagliflozin Taken Twice-daily</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Diagnosis of T2DM Current antihyperglycaemic treatment with metformin immediate release formulation monotherapy &gt;/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. Other treatment with OADs within the 10 weeks prior to enrolment is not permitted. HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and Enrolment Visit 1. Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young (MODY) or secondary causes of diabetes mellitus History of diabetic ketoacidosis Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment FPG &gt;270 mg/dL (&gt;15.0 mmol/L) BMI &gt;45 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metformin treated</keyword>
	<keyword>inadequate control</keyword>
	<keyword>metformin treatment alone</keyword>
</DOC>